Biohaven Pharmaceutical Holding Co Ltd (NYSE:BHVN) – Equities research analysts at Wedbush increased their Q2 2020 EPS estimates for Biohaven Pharmaceutical in a research note issued to investors on Wednesday, July 8th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($1.42) for the quarter, up from their previous estimate of ($1.46). Wedbush has a “Outperform” rating and a $94.00 price target on the stock. Wedbush also issued estimates for Biohaven Pharmaceutical’s Q3 2020 earnings at ($1.36) EPS, Q4 2020 earnings at ($1.36) EPS, FY2020 earnings at ($6.52) EPS, Q1 2021 earnings at ($1.28) EPS, Q2 2021 earnings at ($1.16) EPS, Q3 2021 earnings at ($0.67) EPS, Q4 2021 earnings at ($0.16) EPS, FY2021 earnings at ($3.27) EPS and FY2023 earnings at $7.37 EPS.

Other equities analysts have also recently issued research reports about the stock. Morgan Stanley increased their price objective on shares of Biohaven Pharmaceutical from $46.00 to $50.00 and gave the company an “equal weight” rating in a research note on Monday, May 11th. Canaccord Genuity restated a “buy” rating on shares of Biohaven Pharmaceutical in a research note on Wednesday, April 22nd. Cantor Fitzgerald increased their price objective on shares of Biohaven Pharmaceutical from $82.00 to $109.00 and gave the company an “overweight” rating in a research note on Tuesday, June 23rd. Mizuho started coverage on shares of Biohaven Pharmaceutical in a research note on Friday, June 26th. They issued a “buy” rating and a $85.00 price objective for the company. Finally, Oppenheimer restated a “hold” rating and issued a $41.00 price objective on shares of Biohaven Pharmaceutical in a research note on Friday, May 8th. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $76.91.

Shares of Biohaven Pharmaceutical stock opened at $69.55 on Monday. Biohaven Pharmaceutical has a fifty-two week low of $26.56 and a fifty-two week high of $78.75. The firm has a fifty day moving average price of $68.75 and a two-hundred day moving average price of $51.26. The company has a market cap of $4.34 billion, a PE ratio of -5.51 and a beta of 1.43.

Biohaven Pharmaceutical (NYSE:BHVN) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($2.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.46) by $0.07. The company had revenue of $1.10 million during the quarter, compared to the consensus estimate of $0.21 million. During the same period last year, the company earned ($1.41) earnings per share.

Large investors have recently modified their holdings of the business. Capital International Investors increased its position in shares of Biohaven Pharmaceutical by 105.5% in the 1st quarter. Capital International Investors now owns 6,003,735 shares of the company’s stock valued at $204,307,000 after buying an additional 3,082,031 shares in the last quarter. BlackRock Inc. increased its position in shares of Biohaven Pharmaceutical by 12.1% in the 1st quarter. BlackRock Inc. now owns 3,271,169 shares of the company’s stock valued at $111,318,000 after buying an additional 352,828 shares in the last quarter. Wellington Management Group LLP increased its position in shares of Biohaven Pharmaceutical by 102.5% in the 1st quarter. Wellington Management Group LLP now owns 3,118,373 shares of the company’s stock valued at $106,120,000 after buying an additional 1,578,708 shares in the last quarter. Capital World Investors increased its position in shares of Biohaven Pharmaceutical by 33.5% in the 1st quarter. Capital World Investors now owns 2,197,854 shares of the company’s stock valued at $74,793,000 after buying an additional 551,428 shares in the last quarter. Finally, State Street Corp increased its position in shares of Biohaven Pharmaceutical by 3.4% in the 1st quarter. State Street Corp now owns 1,975,941 shares of the company’s stock valued at $67,241,000 after buying an additional 64,533 shares in the last quarter. 97.15% of the stock is owned by hedge funds and other institutional investors.

In other news, SVP Kimberly Gentile sold 600 shares of the firm’s stock in a transaction dated Monday, June 8th. The shares were sold at an average price of $70.05, for a total value of $42,030.00. Following the transaction, the senior vice president now owns 4,239 shares of the company’s stock, valued at approximately $296,941.95. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Robert Berman sold 61,314 shares of the firm’s stock in a transaction dated Thursday, June 18th. The shares were sold at an average price of $75.27, for a total transaction of $4,615,104.78. Following the completion of the transaction, the insider now directly owns 36,655 shares in the company, valued at approximately $2,759,021.85. The disclosure for this sale can be found here. In the last three months, insiders have sold 849,662 shares of company stock worth $59,372,838. Insiders own 19.10% of the company’s stock.

Biohaven Pharmaceutical Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials and is in long-term safety ongoing process for acute treatment and prevention of migraine; BHV-3500 that has completed phase I clinical trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias.

Featured Article: Preferred Stock

Earnings History and Estimates for Biohaven Pharmaceutical (NYSE:BHVN)

Receive News & Ratings for Biohaven Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.